Human Reproduction Update Advance Access originally published online on October 27, 2005
Human Reproduction Update 2006 12(2):159-168; doi:10.1093/humupd/dmi045
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis
1 Department of Obstetrics and Gynecology, University Clinic of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany and 2 Centre of Reproductive Medicine, Dutch Speaking, Brussels Free University, Brussels, Belgium
3 To whom correspondence should be addressed at: Ratzeburger Allee 160, 23538 Luebeck. E-mail: georg.griesinger{at}frauenklinik.uni-luebeck.de
Submitted on May 23, 2005; resubmitted on July 28, 2005; accepted on September 27, 2005
Triggering final oocyte maturation with GnRH agonist during ovarian stimulation is feasible when inhibition of premature LH surge is performed with GnRH antagonists, and we aimed to systematically collate evidence on the clinical efficacy of GnRH agonist triggering in patients undergoing assisted reproduction in GnRH antagonist protocols. Twenty-three publications were identified by a comprehensive literature search that included PubMed, Embase and the Cochrane Library. Three publications out of 23 fulfilled the inclusion criteria for meta-analysis, which were (i) prospective, randomized controlled study design; (ii) stimulation with gonadotropins for induction of multifollicular development; (iii) suppression of endogenous LH by a GnRH antagonist; (iv) triggering of final oocyte maturation with GnRH agonist; (v) control group randomized to receive HCG for final oocyte maturation and (vi) any means of luteal phase support other than HCG. The participants were normoovulatory women undergoing IVF. The outcomes assessed were clinical pregnancy per randomized patient; number of oocytes retrieved; proportion of metaphase II oocytes; fertilization rate; embryo quality score; first trimester abortion rate; ovarian hyperstimulation syndrome (OHSS) incidence. Results are presented as combined standardized differences of the mean and combined odds ratios, as appropriate, with 95% confidence intervals. No significant difference was found for the number of oocytes retrieved (–0.94, –0.33–0.14), proportion of metaphase II oocytes (–0.03, –0.58–0.52), fertilization rate (0.15, –0.09–0.38) or embryo quality score (0.05, –0.18–0.29). No OHSS occurred in two of the studies, whereas in one study OHSS incidence was not reported. Thus from the available data, no conclusion can be drawn as regards OHSS incidence after GnRH agonist triggering. In comparison to HCG, GnRH agonist administration is associated with a significantly reduced likelihood of achieving a clinical pregnancy (0.21, 0.05–0.84; P = 0.03). The odds of first trimester pregnancy loss is increased after GnRH agonist triggering; however, the confidence interval crosses unity (11.51, 0.95–138.98; P = 0.05). In conclusion, the use of GnRH agonist to trigger final oocyte maturation in IVF, where inhibition of premature LH surge is achieved with GnRH antagonists, yields a number of oocytes capable to undergo fertilization and subsequent embryonic cleavage, which is comparable to that achieved with HCG. However, the likelihood of an ongoing clinical pregnancy after GnRH agonist triggering is significantly lower as compared to standard HCG treatment.
Key words: GnRH agonist / GnRH antagonist / meta-analysis / oocyte maturation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Griesinger, S. von Otte, A. Schroer, A.K. Ludwig, K. Diedrich, S. Al-Hasani, and A. Schultze-Mosgau Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study Hum. Reprod., May 1, 2007; 22(5): 1348 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fister, A. R. Gunthert, G. Emons, and C. Grundker Gonadotropin-Releasing Hormone Type II Antagonists Induce Apoptotic Cell Death in Human Endometrial and Ovarian Cancer Cells In vitro and In vivo Cancer Res., February 15, 2007; 67(4): 1750 - 1756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U.-H. Stenman, A. Tiitinen, H. Alfthan, and L. Valmu The classification, functions and clinical use of different isoforms of HCG Hum. Reprod. Update, November 1, 2006; 12(6): 769 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kol Agonist trigger in the context of OHSS prevention: primum non nocere Hum. Reprod. Update, May 1, 2006; 12(3): 327 - 328. [Full Text] [PDF]
|
|